MENU
About Us

Agilent is a global leader in life science, diagnostics, and analytical laboratory technologies. Now growing in the cell analysis space, Agilent instruments, software, services, solutions, and people provide trusted answers to our customers' most challenging questions.

What started as a unique offering of solutions focused on understanding cellular functionality based on underlying metabolic programming has transformed into a set of innovative tools with the additions of ACEA Biosciences and BioTek Instruments – providing customers the tools they need to uncover unique cell biology, discover novel drug targets, improve preclinical in vitro toxicology, and pioneer the next generation of immunotherapies.

Explore a breadth of solutions in real-time, impedance-based analysis of cell function, real-time cell metabolism, cell imaging and microscopy, microplate readers, microplate washers, flow cytometers, and more.
 
For Research Use Only. Not for use in diagnostic procedures.

DEC 9 - 10 2020

Drug Discovery and Development

Accelerate Your Drug Discoveries with Live Cell Analysis

As the cost of bringing new drugs to market continues to grow, so do the pressures around increasing efficiency and productivity throughout the discovery and development cycle. And, no matter the stage, cell based analysis plays a critical role whether that be in discovery stages where you're identifying new potential targets, in screening where you're modifying the target, or in toxicity studies where you're examining adverse effects on targets. 

Join us for our two-day Agilent Cell Analysis Drug Discovery and Development live conference. Agilent, and BioTek, the newest member of the Agilent family, will be showcasing their latest innovations in cell analysis for drug discovery research including interactive booths, scientific posters and live chat with product experts. There will also be a series of presentations from industry leaders who will discuss how they’ve adopted cell-based assays in their work to increase efficiency and productivity across:

  • Target identification and validation
  • Screening
  • Cardiosafety and mitochondrial toxicity studies
  • Biologics stability and ADME toxicology
     

Discover how leading researchers worldwide are conducting novel research in drug discovery and development, and how Agilent provides key technologies and solutions to advance their therapeutic opportunities through the different stages of drug development:
 

  • Seahorse XF technology measures the two major metabolic pathways, glycolysis and mitochondrial respiration, for live cells in real-time allowing you to expand your drug discovery pipeline by targeting these pathways, assessing compounds for mitochondrial toxicity, and better understanding their mechanisms.
     
  • Soluble Metabolic Sensors MitoXpress & pH-Xtra Products provide a high throughput, mix-and-measure, plate reader assessment of mitochondrial function and cell metabolism for investigating microbial metabolism, screening for antimicrobial compounds, as well as Anti-parasitic drug screening and drug target discovery.
     
  • Identify cardiotoxic effects by monitoring contractile, structural, and ion channel activity in real time using the xCELLigence real-time cell analysis (RTCA) Cardio/CardioECR/ePacer systems.
     
  • NovoCyte flow cytometers provide robust, sensitive and automated quantitative assays relevant to drug discovery and development such as immunophenotyping and cell cycle analysis.
     
  • Synergy Neo2 Multi-Mode Microplate Reader provides sensitivity and speed for biochemical and cell-based screening applications.
     
  • A wide range of microplate dispensing and washing products including EL406 Combination Washer Dispenser, 405 LS Microplate Washer and MultiFlo FX Multi-Mode Dispenser delivers high precision, cost-effective benchtop automation for any level of sample throughput in screening, lead optimization and ADME/Tox applications.
     
  • The Cytation platform combines microplate reader optics with automated digital widefield microscopy coupled with a broad range of quantitative image analysis metrics.  Designed specifically to enable both target-based and phenotypic cell-based assays, with either fixed or live cells, Cytation is ready for any assay. 

For Research Use Only. Not for use in diagnostic procedures.


Speakers
  • Emily Dunkelberger, PhD

    Staff Scientist, Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health
    BIOGRAPHY
  • Chris Pudney, PhD

    Associate Professor of Biophysics, University of Bath; Director, BLOC Laboratories Ltd
    BIOGRAPHY
  • Charly Chahwan, PhD

    Co Founder, CSO at SyntheX, Inc.
    BIOGRAPHY
  • Victor Darley-Usmar, Ph.D.

    Associate Dean for Research, Endowed Professor in Mitochondrial Medicine and Pathology, University of Alabama at Birmingham
  • Sandra Milasta, PhD

    Senior Scientist, Immunotherapy, Pre-clinical Development, Elevatebio
  • Joy Feng, PhD

    Principal Scientist, Gilead Sciences, Inc.
    BIOGRAPHY

Speakers


  • Emily Dunkelberger, PhD

    Emily Dunkelberger, PhD

    Staff Scientist, Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health

    BIOGRAPHY
  • Chris Pudney, PhD

    Chris Pudney, PhD

    Associate Professor of Biophysics, University of Bath; Director, BLOC Laboratories Ltd

    BIOGRAPHY
  • Charly Chahwan, PhD

    Charly Chahwan, PhD

    Co Founder, CSO at SyntheX, Inc.

    BIOGRAPHY
  • Victor Darley-Usmar, Ph.D.

    Victor Darley-Usmar, Ph.D.

    Associate Dean for Research, Endowed Professor in Mitochondrial Medicine and Pathology, University of Alabama at Birmingham

  • Sandra Milasta, PhD

    Sandra Milasta, PhD

    Senior Scientist, Immunotherapy, Pre-clinical Development, Elevatebio

  • Joy Feng, PhD

    Joy Feng, PhD

    Principal Scientist, Gilead Sciences, Inc.

    BIOGRAPHY

Agenda

  • DEC 10, 2020 1:00 PM EST

    Using an unbiased drug discovery platform to uncover a novel immunogenic cell death

    Charly Chahwan, PhD
    Co Founder, CSO at SyntheX, Inc.
    BIOGRAPHY
  • DEC 10, 2020 11:30 AM EST

    Mechanism-based Off-target Screening De-risks Clinical Development of Antiviral Nucleoside/tide Drugs

    Joy Feng, PhD
    Principal Scientist, Gilead Sciences, Inc.
    BIOGRAPHY
  • DEC 09, 2020 1:00 PM EST

    Using Physical Chemistry and a High-Throughput Drug Screen to Find a Drug to Treat Sickle Cell Disease

    Emily Dunkelberger, PhD
    Staff Scientist, Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health
    BIOGRAPHY
  • DEC 09, 2020 11:30 AM EST

    QUBES: A rapid approach for predicting the stability of proteins

    Chris Pudney, PhD
    Associate Professor of Biophysics, University of Bath; Director, BLOC Laboratories Ltd
    BIOGRAPHY
  • Defining the Bioenergetic Metabolite Interactome in Human Subjects

    Victor Darley-Usmar, Ph.D.
    Associate Dean for Research, Endowed Professor in Mitochondrial Medicine and Pathology, University of Alabama at Birmingham
  • Metabolic regulation of adaptive immune cell function

    Sandra Milasta, PhD
    Senior Scientist, Immunotherapy, Pre-clinical Development, Elevatebio
  • QUBES: A rapid approach for predicting the stability of proteins
  • DEC 09, 2020 11:30 AM EST

    QUBES: A rapid approach for predicting the stability of proteins

    Chris Pudney, PhD
    Associate Professor of Biophysics, University of Bath; Director, BLOC Laboratories Ltd
    BIOGRAPHY
  • Using Physical Chemistry and a High-Throughput Drug Screen to Find a Drug to Treat Sickle Cell Disease
  • DEC 09, 2020 1:00 PM EST

    Using Physical Chemistry and a High-Throughput Drug Screen to Find a Drug to Treat Sickle Cell Disease

    Emily Dunkelberger, PhD
    Staff Scientist, Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health
    BIOGRAPHY
  • Using an unbiased drug discovery platform to uncover a novel immunogenic cell death
  • DEC 10, 2020 1:00 PM EST

    Using an unbiased drug discovery platform to uncover a novel immunogenic cell death

    Charly Chahwan, PhD
    Co Founder, CSO at SyntheX, Inc.
    BIOGRAPHY
Help

Connect with us